Det anbefales dig at regulere dosis eller infusionstiden hos patienter, der bliver behandlet for forebyggelse af knoglerelaterede hændelser hos patienter med brystkræft og knoglemetastaser (se pkt.
However, an adjustment in the dose or infusion time is recommended in patients being treated for the prevention of skeletal events in patients with breast cancer and bone metastases (see section 4.2).